Recordati stock stands 5.71 percent above EUR 50.00 Hold target

Published on 10/14/2026 at 17:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half revenue rose 6.60 percent to EUR 1.40 billion. Recordati stock was EUR 53.03 on October 14, 2026, 0.15 percent above Xetra's close.

Analyst view and reporting date

On October 13, 2026, the latest Hold rating carried a EUR 50.00 target for Recordati.
First-half 2026 revenue rose 6.60 percent to EUR 1.40 billion.
Recordati stock costs EUR 53.03 at Lang & Schwarz on October 14, 2026 at 5:05 p.m. CEST, plus 0.15 percent versus the Xetra close of October 13, 2026.
Recordati is scheduled to release third-quarter 2026 results on November 10, 2026.

Bauhaus-Poster mit geometrischen Formen und dem Wort PHARMA in kräftigen Farben — Recordati S.p.A. (IT0003828271) wird hier als Pharma-Unternehmen durch ein geometrisches Bauhaus-Poster mit Sektor-Kürzel symbolisiert, Illustration mit AI erstellt.

Recordati stock stands 5.71 percent above the latest Hold target of EUR 50.00. According to The Globe and Mail on October 13, 2026, the most recent analyst rating on Recordati was Hold with a EUR 50.00 price target. The price lies 5.71 percent below that target. Recordati was trading at EUR 53.03 at Lang & Schwarz on October 14, 2026 at 5:05 p.m. CEST, plus 0.15 percent versus the Xetra close of October 13, 2026 at EUR 52.95.

First-half revenue rises 6.60 percent

Recordati's latest reported period also gives the stock a measurable operating benchmark. In the first half of 2026, revenue increased 6.60 percent to EUR 1.40 billion, while EBITDA rose 8.80 percent to EUR 540.00 million and the margin reached 38.30 percent, according to Yahoo Finance in its July 29, 2026 earnings-call transcript.

Reported net income rose 24.80 percent to EUR 269.70 million in the same period, while free cash flow reached EUR 299.00 million. The combination of revenue growth and a 38.30 percent EBITDA margin explains why the EUR 50.00 target sits below the current market price.

Stock sits 2.61 percent below yearly high

The Lang & Schwarz quote is EUR 1.42 below Recordati's 52-week high of EUR 54.45 and EUR 9.27 above its 52-week low of EUR 43.76. The current price is therefore 2.61 percent below the high and 21.18 percent above the low.

The bid is EUR 53.00 and the ask is EUR 53.05. Trading volume was 284,436 shares, compared with an average volume of 334,202 shares, a difference of 14.92 percent.

Valuation and November reporting date

Recordati has a market capitalization of EUR 10.8 billion and a price-to-earnings ratio of 22.27 on the Borsa Italiana listing. The company is scheduled to release third-quarter 2026 results on November 10, 2026, according to MarketScreener.

Recordati trades as REC.MI on Borsa Italiana under ISIN IT0003828271, as reported by Global Banking and Finance. The listing is in the healthcare sector and the company operates specialty and primary-care pharmaceutical businesses.

Comparison with peers

Recordati: plus 0.15 percent, P/E 22.27, market capitalization EUR 10.8 billion.

Ipsen (Euronext Paris, EUR): plus 1.54 percent, P/E 23.43, market capitalization EUR 12.0 billion.

UCB (Euronext Brussels, EUR): plus 2.37 percent, P/E 17.53, market capitalization EUR 38.6 billion.

Price remains near yearly high

Recordati was trading at EUR 53.03 at Lang & Schwarz on October 14, 2026 at 5:05 p.m. CEST, plus 0.15 percent versus the Xetra close of October 13, 2026 at EUR 52.95. The price remains 2.61 percent below the 52-week high of EUR 54.45.

The further course of trading is shown by the continuously updated real-time quote of Recordati stock.